FDA
-
-
-
-
-
-
-
Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights
-
-
-
-
-
-
-
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
-
-
-
-
-
-
-
Renalytix partners with Tempus AI to expand kidney disease testing
-
-
-
-
-
-
-
Tempus receives FDA clearance for heart condition detection software
-
-
-
-
-
-
-
AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs
-
-
-
-
-
-
-
Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis
-
-
-
-
-
-
-
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

